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Background: Guidelines recommend waiting at least 5 days after clopidogrel discontinuation prior to cardiac surgery. The objective of this study 
was to examine time to surgery in clopidogrel-exposed (CE) patients using a platelet function guided strategy compared to standard of care.
Methods: Consecutive in-patients who underwent cardiac surgery at our institution over a 2 year period were identified retrospectively. Baseline 
and procedural characteristics were extracted through the medical record. CE was defined as use of clopidogrel within 5 days prior to or on day of 
admission. Clopidogrel was not continued on admit orders. Thirty day outcomes were assessed through the Society of Thoracic Surgeons database. 
Inclusion criteria included CE at the time of hospitalization, in-patient status, and need for cardiac surgery.
CE patients had platelet function analyzed on a daily basis by a VerifyNow P2Y12 receptor assay per local practice. Patients were considered eligible 
for surgery when platelet reactivity was > 240 PRU. Primary outcome was time from admission to surgery in days. Analysis of variance, t-test, and 
Fisher’s exact test were used as appropriate.
Results: Of 112 patients, 39 had CE while 73 had no exposure (NE). Baseline characteristics of CE and NE did not differ with the exception of body 
mass index (30.9 +/- 1.0 vs. 27.5 +/- 0.7, p=0.007) and use of glycoprotein IIb/IIIa inhibitor (9% vs. 0%, p = 0.03) both of which were greater in CE 
patients.
The mean time to cardiac surgery in CE patients was 3.64 +/- 0.99 days. There were no significant differences in blood product use, incidence of 
significant bleeding, 30-day re-hospitalization, or 30-day mortality between CE and NE patients.
Conclusion: On average, clopidogrel-exposed patients went to surgery earlier than 5 days from discontinuation. Despite this, there were no 
significant differences in post operative bleeding, re-hospitalization, and 30 day mortality between clopidogrel-exposed and non-exposed patients. 
Using a platelet function guided approach for clopidogrel-exposed patients may safely reduce time to cardiac surgery when compared to current 
guideline recommendations.
